Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
KYNTRA BIO INC reported $6.4M in revenue and $183.5M in net income for fiscal 2025.
See the full KYNB financial statements: income statement, balance sheet, cash flow and ratios, each column linked to its SEC filing.
Kyntra Bio to Present at the H.C. Wainwright 28th Annual Global Investment Conference
CEO Thane Wettig’s Sept. 15, 4:00 PM ET presentation will stream live and replay for 90 days via webcast.
Kyntra Bio (KYNB) will present at the H.C. Wainwright 28th Annual Global Investment Conference in New York from September 14–16, 2026. CEO Thane Wettig is scheduled to give a company presentation on Tuesday, September 15 at 4:00 PM ET, which will be available via live webcast with a 90-day replay.
Loading...
Loading translation...
Positive
None.
Negative
None.
Market Reaction – KYNB
+6.42%$8.462.1x vol
15m delay
+6.42%Vs previous close
$8.46Last Price
$7.91$8.66Day Range
$34.26MMarket Cap
2.1xRel. Volume
Following this news, KYNB has gained 6.42%, reflecting a notable positive market reaction.
Our momentum scanner has triggered 12 alerts so far, indicating notable trading interest and price volatility.
The stock is currently trading at $8.46.
Trading volume is elevated at 2.1x the average, suggesting notable buying interest.
The stock is up +6.4% following this news. KYNB rose 6.25% after the May 11 earnings report, providi...
Analysis
The stock is up +6.4% following this news. KYNB rose 6.25% after the May 11 earnings report, providing a prior company-specific positive-news reference. A strong response to this conference presentation would warrant separating commentary from new clinical evidence, which the announcement did not disclose.
Loss narrowed, cash remained substantial, and pipeline development continued.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Pattern Detected
Positive clinical and balance-sheet announcements were followed by gains, while a routine earnings-date notice was followed by a decline.
Key Terms
antibody-drug conjugate, pet biomarker, chronic kidney disease, myelodysplastic syndrome, +1 more
5 terms
antibody-drug conjugatemedical
"a first-in-class antibody-drug conjugate (ADC) targeting CD46"
An antibody-drug conjugate is a targeted medicine that combines an antibody, which can identify specific cells, with a powerful drug designed to destroy those cells. This approach allows for precise treatment, minimizing damage to healthy tissue. For investors, developments in this area can signal advances in cancer therapies and potential growth opportunities in the biotech sector.
pet biomarkermedical
"the development of FG-3180, an associated CD46-targeted PET biomarker"
A pet biomarker is a measurable biological sign in an animal—such as a molecule in blood, an image finding, or a physiological reading—that indicates disease presence, progression, or response to treatment. Like a car’s dashboard light that signals a specific problem, these markers can make health status easier to detect and track, which matters to investors because they can enable diagnostic products, guide drug development, reduce trial time and cost, and create commercial services in veterinary and comparative medicine.
chronic kidney diseasemedical
"anemia in chronic kidney disease (CKD) patients"
Chronic kidney disease is a long-term, progressive loss of kidney function that reduces the organs’ ability to filter waste, control fluid levels and balance body salts. For investors, CKD matters because it creates sustained demand for tests, drugs, dialysis machines and transplants; advances in treatment or regulatory decisions can meaningfully change revenue prospects for companies—like a car that needs ongoing repairs, it creates predictable, long-term market needs.
myelodysplastic syndromemedical
"anemia associated with lower-risk myelodysplastic syndrome (LR-MDS)"
A bone marrow disorder in which the body’s blood-cell “factory” produces too few or abnormal blood cells, leading to anemia, infections, or bleeding and sometimes progressing to acute leukemia. Investors care because the condition creates clinical and commercial opportunities — drugs, tests and treatments that improve blood counts or delay progression can drive regulatory approvals, patient demand and reimbursement decisions, affecting the value of healthcare and biotech companies.
phase 3 trialmedical
"evaluate the development plan for the Phase 3 trial"
A Phase 3 trial is a large, late-stage test of a new drug or medical treatment done on many people to make sure it really works and is safe. For investors, it matters because a successful Phase 3 usually means the company can ask regulators to sell the product and could earn lots of money, while failure can sharply reduce the company’s value.
SAN FRANCISCO, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kyntra Bio (Nasdaq: KYNB) today announced that the company’s management will be attending and presenting at the H.C. Wainwright 28th Annual Global Investment Conference being held September 14-16, 2026, in New York, NY.
Thane Wettig, Chief Executive Officer of Kyntra Bio, will deliver a company presentation on Tuesday, September 15 at 4:00 PM ET. A live webcast of the presentation will be available here.
Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright. The live audio webcast of the event will also be available to investors and other interested parties on the “Events & Presentations” section of the Kyntra Bio Investor webpage at www.kyntrabio.com. The replay will be available for 90 days following the event.
About Kyntra Bio Kyntra Bio is a biopharmaceutical company focused on development of novel therapies in oncology and rare disease. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in Europe, Japan, China, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.kyntrabio.com.
For Investor Inquiries: David DeLucia, CFA Senior Vice President and Chief Financial Officer ir@kyntrabio.com
FAQ
When will Kyntra Bio (KYNB) present at the H.C. Wainwright 28th Annual Global Investment Conference?
Kyntra Bio’s CEO, Thane Wettig, will present on Tuesday, September 15, 2026, at 4:00 PM ET during the H.C. Wainwright 28th Annual Global Investment Conference in New York.
How can investors access the Kyntra Bio (KYNB) presentation webcast from the H.C. Wainwright conference?
A live audio webcast of Kyntra Bio’s presentation will be available via a conference link and in the “Events & Presentations” section of the Kyntra Bio investor webpage at www.kyntrabio.com.
Will a replay of the Kyntra Bio (KYNB) H.C. Wainwright conference presentation be available?
Yes. A replay of the Kyntra Bio presentation audio webcast will be available on the company’s investor webpage for 90 days following the event.
Can investors schedule one-on-one meetings with Kyntra Bio (KYNB) at the H.C. Wainwright 2026 conference?
Yes. Kyntra Bio’s management team will be available for one-on-one meetings during the conference. Interested investors should contact their representative at H.C. Wainwright to arrange meetings.
What does Kyntra Bio (KYNB) focus on in its biopharmaceutical pipeline?
Kyntra Bio focuses on developing novel therapies in oncology and rare disease. Its pipeline includes roxadustat for anemia indications and FG-3246, a CD46-targeting antibody-drug conjugate, along with the FG-3180 CD46-targeted PET biomarker.
What clinical programs of Kyntra Bio (KYNB) are highlighted in this announcement?
The announcement highlights roxadustat, approved in multiple countries for anemia in CKD, with a Phase 3 plan under evaluation for LR-MDS in the U.S., and FG-3246, a first-in-class CD46-targeting ADC in Phase 2 for metastatic castration-resistant prostate cancer, plus the FG-3180 PET biomarker.
